Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

NCT05430919 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergic Rhinitis
Conjunctivitis

Interventions

DRUG: REGN5713
DRUG: REGN5714
DRUG: REGN5715
OTHER: Placebo

Sponsor

Regeneron Pharmaceuticals